Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial
Journal of Radiation Research · 2024
DOI: 10.1093/jrr/rrae026 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Radiation Research, 2024. Verfasst von Motohiro Murakami und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8576, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proton Therapy, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The usefulness of moderately hypofractionated radiotherapy for localized prostate cancer has been extensively reported, but there are limited studies on proton beam therapy (PBT) using similar hypofractionation schedules. The aim of this prospective phase II study is to confirm the safety of a shortened PBT course using 70 Gy relative biological effectiveness (RBE) in 28 fractions. From May 2013 to June 2015, 102 men with localized prostate cancer were enrolled. Androgen deprivation therapy was administered according to risk classification. Toxicity was assessed using Common Terminology Criteria for Adverse Events version 4.0. Of the 100 patients ultimately evaluated, 15 were classified as low risk, 43 as intermediate risk, and 42 as high risk. The median follow-up time of the surviving patients was 96 months (range: 60–119 months). The 5-year cumulative incidences of grade 2 gastrointestinal/genitourinary adverse events were 1% (95% CI: 0.1–6.9) and 4% (95% CI: 1.5–10.3), respectively; no grade ≥ 3 gastrointestinal/genitourinary adverse events were observed. The current study revealed a low incidence of late adverse events in prostate cancer patients treated with moderately hypofractionated PBT of 70 Gy (RBE) in 28 fractions, indicating the safety of this schedule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8576, Japan.
- QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
- JCOG Data Center and Operations Office, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuuo-ku, Tokyo, 104-0045, Japan.
- Department of Urology, Faculty of Medicine and Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8576, Japan.
- Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan.
- Department of Radiology, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuuo, Ami-machi, inashiki-gun, Ibaraki, 300-0395, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Murakami, M., Ishikawa, H., Sekino, Y., Nishiyama, H., Suzuki, H., Sugahara, S., Iizumi, T., Mizumoto, M., Okumura, T., Keino, N., Iizumi, Y., Hashimoto, K., Gosho, M., & Sakurai, H. (2024). Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrae026
Vancouver
Murakami M, Ishikawa H, Sekino Y, Nishiyama H, Suzuki H, Sugahara S, et al. Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. 2024. doi:10.1093/jrr/rrae026
BibTeX
@article{Murakami2024,
author = {Murakami, Motohiro and Ishikawa, Hitoshi and Sekino, Yuta and Nishiyama, Hiroyuki and Suzuki, Hiroyoshi and Sugahara, Shinji and Iizumi, Takashi and Mizumoto, Masashi and Okumura, Toshiyuki and Keino, Naoto and Iizumi, Yuichi and Hashimoto, Koichi and Gosho, Masahiko and Sakurai, Hideyuki},
title = {Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial},
journal = {Journal of Radiation Research},
year = {2024},
doi = {10.1093/jrr/rrae026}
}
EUVIMED